Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
Codexis, Inc.,today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited for the research and development of an additional gene therapy for a lysosomal storage disorder bringing
June 11, 2021
by firstwordpharma
Codexis Signs Strategic Collaboration, License Agreement with Takeda
Codexis has announced the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical for the research and development of novel gene therapies ...
March 27, 2020
by americanpharmaceuticalreview
Takeda partners with Codexis on gene therapies for rare diseases
Takeda Pharmaceutical has signed a strategic collaboration and licence agreement with biotherapeutics developer Codexis to research and create gene therapies for rare disorders.
March 25, 2020
by pharmaceutical-technology
Codexis, Takeda Sign Gene Therapy Collaboration
Partnership to leverage Codexis’ protein engineering platform to advance novel gene therapies for rare genetic disorders。
March 25, 2020
by contractpharma
Codexis Names SVP, and CFO
Taylor to succeed Sangster, responsible for managing all aspects of financial, accounting, investor relations, and corporate administrative functions.
August 9, 2019
by contractpharma
Codexis, Novartis Ink Tech Transfer and License Agreement
Novartis to leverage CodeEvolver protein engineering platform technology develop performance enzymes for use in manufacturing.
May 16, 2019
by contractpharma
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114
July 10, 2018
by firstwordpharma